Want to see JP:4571 full AI Analyst Report?

NanoCarrier Co., Ltd. (4571) Price & Analysis

2 Followers

4571 Stock Chart & Stats

¥134.00

-¥1.00(-0.68%)

At close: Jan 08 4:00 PM EST

¥134.00

-¥1.00(-0.68%)

Day’s Range― - ―

52-Week Range¥93.00 - ¥254.00

Previous CloseN/A

Volume236.30K

Average Volume (3M)2.35M

Market Cap

¥8.54B

Enterprise Value¥5.36K

Total Cash (Recent Filing)¥4.91B

Total Debt (Recent Filing)¥1.60B

Price to Earnings (P/E)―

Beta0.92

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-12.91

Shares Outstanding83,796,760

10 Day Avg. Volume484,410

30 Day Avg. Volume2,345,523

Financial Highlights & Ratios

PEG Ratio-1.32

Price to Book (P/B)3.10

Price to Sales (P/S)63.30

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue RecoveryStrong revenue rebound in 2026 signals regained commercial traction or milestone-driven receipts from collaborators. This durable top-line recovery can improve partner confidence, fund clinical programs via milestone/licensing deals, and reduce the probability of prolonged decline even if profitability remains distant.

High Gross MarginsConsistently high gross margins indicate attractive unit economics for the micelle delivery platform and partner-funded sales. Durable gross profitability affords operating leverage as revenues scale, enabling more R&D or margin capture via licensing without reliance on sheer volume growth.

Partnership/licensing ModelA business model focused on collaborations and licensing is structurally capital-efficient for a development-stage biotech. It shifts commercialization and capex burden to partners, creates milestone-driven non-dilutive cash inflections, and scales revenue potential without building a full commercial infrastructure.

Bears Say

Persistent Operating LossesPersistent, deep operating and net losses indicate the company remains far from break-even despite revenue gains. Ongoing negative profitability erodes retained earnings, weakens investor optionality, and raises the likelihood of further financing or curtailed R&D if losses are not sustainably reduced.

Negative Operating Cash FlowConsistently negative operating cash flow and mostly negative free cash flow mean the core business consumes cash instead of funding itself. This structural cash burn forces reliance on external financing, increasing dilution or debt risk and constraining long-term investment flexibility.

Rising Debt & Weakening EquityTotal debt rising to ¥1.6B while assets and equity decline reduces balance-sheet flexibility. Although leverage remains moderate, increasing indebtedness combined with negative ROE (-23% to -38%) heightens refinancing risk and limits capacity to weather clinical or commercial setbacks.

NanoCarrier Co., Ltd. News

Nano Holdings Begins First-in-Human mRNA Trial Targeting Knee Osteoarthritis

NanoCarrier Co., Ltd. ( ($JP:4571) ) has provided an announcement. Nano Holdings, Inc., a Japan-based healthcare value creation...

6M ago

NANO MRNA Advances RUNX1 mRNA Clinical Trial for Osteoarthritis

The latest announcement is out from NanoCarrier Co., Ltd. ( ($JP:4571) ). NANO MRNA Co., Ltd., through its...

11M ago

4571 FAQ

What was NanoCarrier Co., Ltd.’s price range in the past 12 months?

NanoCarrier Co., Ltd. lowest stock price was ¥93.00 and its highest was ¥254.00 in the past 12 months.

What is NanoCarrier Co., Ltd.’s market cap?

NanoCarrier Co., Ltd.’s market cap is ¥8.54B.

When is NanoCarrier Co., Ltd.’s upcoming earnings report date?

NanoCarrier Co., Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 83 days.

How were NanoCarrier Co., Ltd.’s earnings last quarter?

NanoCarrier Co., Ltd. released its earnings results on Aug 07, 2026. The company reported -¥3.39 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is NanoCarrier Co., Ltd. overvalued?

According to Wall Street analysts NanoCarrier Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NanoCarrier Co., Ltd. pay dividends?

NanoCarrier Co., Ltd. does not currently pay dividends.

What is NanoCarrier Co., Ltd.’s EPS estimate?

NanoCarrier Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NanoCarrier Co., Ltd. have?

NanoCarrier Co., Ltd. has 83,796,760 shares outstanding.

What happened to NanoCarrier Co., Ltd.’s price movement after its last earnings report?

NanoCarrier Co., Ltd. reported an EPS of -¥3.39 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.01%.

Which hedge fund is a major shareholder of NanoCarrier Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4571

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NanoCarrier Co., Ltd.

NANO MRNA Co., Ltd. specializes in the discovery, advancement, and manufacturing of pharmaceutical products, employing its innovative micellar nanoparticle platform. Its biopharmaceutical pipeline is primarily geared towards addressing oncological conditions and a range of other severe illnesses. The enterprise also undertakes the full spectrum of activities for anti-cancer medications, from initial scientific investigation to market commercialization, all underpinned by its distinctive micellar nanoparticle approach. Established on June 14, 1996, by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi, the firm maintains its principal operations in Tokyo, Japan.